The National Institutes of Health is teaming with government, biopharmaceutical, life science and non-profit organizations to overcome obstacles and increase success for advancing promising treatments for Parkinson’s disease (PD). Read More »

Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial Read More »

Mallinckrodt plc confirmed enrollment of the first patient in the company's Phase 4, multi-center, randomized, double-blind, placebo-controlled pilot study to further assess the efficacy of H.P. Read More »

Upsher-Smith Laboratories, LLC (Upsher-Smith) announced that it has received U.S. Food and Drug Administration (FDA) approval of its abbreviated new drug application (ANDA) for Bumetanide Tablets, USP, 0.5 mg, 1 mg, and 2 mg. Read More »

Proprietary technology enables and helps guide specialty pharmacist interactions with patients prescribed oral oncology medications Read More »

McKesson Medical-Surgical and Sysmex America today announced plans for McKesson to be the exclusive distribution partner for Sysmex's new XW-100 automated hematology analyzer, the first Clinical Laboratory Improvement Amendments (CLIA)-waived, complete blood count (CBC) diagnostic instrument. Read More »

As part of its continued support of the American Heart Association's Go Red For Women movement, CVS Health extended its commitment to women's health by offering no cost Read More »

SomaLogic announced today the establishment of a framework "Partnership for Personalized Health" with the Leeds Centre for Personalised Medicine and Health (CPMH) Read More »

Labcyte issued the following announcement on Feb. 5.Labcyte Inc. today launched the Access™ Dual-Robot System (DRS) and the Echo® 655T Liquid Handler Read More »

Novo Nordisk Inc. issued the following announcement on Feb. 5.Novo Nordisk today announced the availability of two new diabetes medications, Ozempic® (semaglutide) injection 0.5 mg or 1 mg and Fiasp® (insulin aspart injection) 100 Units/mL at pharmacies across the United States. Read More »

Northwell Health has established an innovative biosurveillance system to track and respond to the huge volume of influenza cases coming into its hospitals on Long Island and New York City. Read More »

Novel approach used to simulate patient response through modeling based on previously published literature to provide important treatment sequencing insights for GI community Read More »

Innovative new formulation delivers higher concentration of anti-rabies virus antibodies per mL at wound site compared to other rabies immune globulin products on the market Read More »

Pharmacy Development Services (PDS) announces the 14th Annual PDS Super-Conference on February 22-24th, 2018 in Orlando, Florida. Read More »

National Institutes of Health scientists developing a rapid, practical test for the early diagnosis of prion diseases have modified the assay to offer the possibility of improving early diagnosis of Parkinson’s disease and dementia with Lewy bodies. Read More »

The Pharmaceutical Research and Manufacturers of America (PhRMA) held its board meeting, officially welcoming three new elected officers. Read More »

The Walgreens Flu Index™ is a weekly report developed to provide state- and market-specific information regarding flu activity, and ranks those states and markets experiencing the highest incidences of influenza across the country. Read More »

Boehringer Ingelheim announced that their Phase II Alzheimer’s disease trials with investigational compound BI 409306 had not met their efficacy endpoints and plans for further trials with BI 409306 in AD will therefore not be pursued. Read More »

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, developing targeted cancer therapeutics, today announced that preclinical data demonstrating the synergy of PCM-075, its highly-selective Polo-like kinase 1 (PLK1) Inhibitor, in combination with abiraterone acetate (Zytiga® – Johnson & Johnson) Read More »

Salix Pharmaceuticals, Ltd., one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. have received notice that the U.S. Food and Drug Administration has extended the PDUFA action date for its review of the New Drug Application for PLENVU®* (NER1006) by three months to May 13, 2018. Read More »